Retention of golimumab treatment following discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Musculoskeletal Care. 2022 Jun;20(2):403-407. doi: 10.1002/msc.1595. Epub 2021 Oct 19.
No abstract available

Keywords: axial spondylarthritis; golimumab; medication retention rate; psoriatic arthritis; rheumatoid arthritis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents* / therapeutic use
  • Humans
  • Registries
  • Rheumatic Diseases* / drug therapy
  • Tumor Necrosis Factor-alpha / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • golimumab